Ekso Bionics Holdings, Inc. (EKSO) shares fell 12.75 percent, sliding $0.5802 to $3.97 on Thursday, after the company announced it will become the exclusive U.S. sales agent and distributor for MediTouch's BalanceTutor rehabilitation system. The uses a patented 4D perturbation treadmill to simulate real-world balance challenges, supporting patient safety while improving rehabilitation outcomes.Ekso Bionics is trading at $3.97 versus a previous close of $4.5502 on the Nasdaq. The stock opened at $4.25 and h ...

SAN RAFAEL, Calif. and TNUVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into an agreement with Israel-based MediTouch Inc. (“MediTouch”) to become the exclusive authorized sales agent and distributor of MediTouch’s BalanceTutor™ rehabilitation system in the United States. The BalanceTutor is the only known rehabilitati ...

Core Viewpoint - Ekso Bionics (EKSO) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to institutional investors adjusting their valuations, resulting in buying or selling actions that affect stock prices [4]. Company Performance Indicators - Ekso Bionics is projected to earn -$0.92 per share for the fiscal year ending December 2025, showing no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for Ekso Bionics has increased by 21.4%, reflecting a positive trend in earnings outlook [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of Ekso Bionics to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [10].

Core Insights - Several stocks experienced significant movements in after-hours trading, influenced by earnings announcements and financing updates, particularly in the healthcare and biotech sectors [1] Company Summaries - **PACS Group Inc. (PACS)**: The stock surged 45.48% to $24.48 after a 16.63% increase during regular trading, closing at $16.83. The company reported Q3 net income of $52.4 million ($0.32 per share), up from $15.6 million ($0.10 per share) a year ago. Revenue increased to $1.345 billion from $1.026 billion. For fiscal 2025, PACS expects revenue between $5.25 billion and $5.35 billion, with adjusted EBITDA projected at $480 million to $490 million [2] - **Zynex, Inc. (ZYXI)**: The stock rose 4.49% after hours to $0.58, following a 32.14% gain during regular trading. The company reported a net loss of $42.9 million ($1.42 per share) for the quarter ended September 30, 2025, compared to a net income of $2.3 million ($0.07 per share) in the same period last year. Net revenue fell to $13.4 million from $50.0 million [3] - **Genenta Science S.p.A. (GNTA)**: The stock increased 7.34% after hours to $1.90, recovering from an 11.06% decline to $1.77. Last month, the company announced a securities purchase agreement for 4,285,715 American Depositary Shares at $3.50 per ADS, raising approximately $15.0 million before fees and expenses [4] - **Ekso Bionics Holdings, Inc. (EKSO)**: The stock gained 4.22% in after-hours trading to $4.20, after closing at $4.03, down 3.47% earlier in the day. In late October, the company disclosed a registered direct offering of 769,490 shares priced at $4.81 per share [5] - **Nutex Health Inc. (NUTX)**: The stock advanced 9.64% after hours to $123.00, following a 13.09% rise during regular trading to $112.19. The company reported Q3 net income of $55.4 million, reversing a net loss of $8.8 million in the same period last year. Revenue climbed to $267.8 million, up from $78.8 million, marking a 239.9% increase [6]

Core Points - Ekso Bionics Holdings, Inc. has entered into a definitive agreement for the purchase and sale of 769,490 shares of common stock at a price of $4.81 per share, expected to close around October 30, 2025 [1] - The gross proceeds from this offering are anticipated to be $3.7 million, which will be used for general corporate purposes including research and development, administrative costs, and working capital needs [3] - The shares are being offered under a "shelf" registration statement previously filed with the SEC, and the offering will be conducted via a prospectus [4] Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility for both medical and industrial applications [6] - The company focuses on improving health and quality of life through advanced robotics, and is recognized for its unique technologies that assist individuals with paralysis and enhance capabilities in various job sites [6] - Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO" [6]

Financial Performance - Ekso Bionics reported a quarterly loss of $0.54 per share, better than the Zacks Consensus Estimate of a loss of $0.99, and an improvement from a loss of $1.5 per share a year ago, representing an earnings surprise of +45.45% [1] - The company posted revenues of $4.23 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 8.11%, compared to year-ago revenues of $4.13 million [2] - The current consensus EPS estimate for the upcoming quarter is -$0.54 on revenues of $5.65 million, and for the current fiscal year, it is -$1.17 on revenues of $15 million [7] Stock Performance - Ekso Bionics shares have declined approximately 46.2% since the beginning of the year, contrasting with the S&P 500's gain of 16.9% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical - Instruments industry, to which Ekso Bionics belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Market Performance and Sales - For the Personal Health market, the Ekso Indego Personal device received Medicare reimbursement approval at approximately $91,000, effective April 1, 2024, which is expected to increase demand among the estimated 309,000 individuals living with spinal cord injuries (SCI) in the U.S.[190] - The company anticipates that the majority of its revenue in 2025 will continue to come from Enterprise Health sales, while Personal Health product sales are expected to contribute more quarter over quarter as reimbursement processes are optimized[192] - The company has signed agreements with several partners, including National Seating & Mobility and Ottobock Patient Care, to enhance sales and reimbursement processes for the Ekso Indego Personal device, with expectations of increased claims submissions over the next 12 months[192] - The company is focused on expanding insurance coverage beyond Medicare and seeking additional indications of use for its products, which could significantly drive growth in Personal Health product sales[193] - The company’s revenue is highly dependent on market demand for exoskeleton products, influenced by factors such as awareness among rehabilitation clinics and reimbursement levels from Medicare and private insurers[196] Financial Performance - Revenue for the three months ended September 30, 2025, increased by $0.1 million, or 2%, to $4.227 million compared to $4.129 million in 2024, driven by higher sales volume of Enterprise Health devices in the Americas[212] - Gross profit for the same period increased by $0.3 million to $2.549 million, resulting in a gross margin of 60%, up from 53% in 2024, primarily due to lower device costs associated with multiple-device sales[213][214] - Total operating expenses decreased by $0.9 million, or 19%, to $3.951 million for the three months ended September 30, 2025, with significant reductions in sales and marketing (25%) and research and development (29%) expenses[216][217] - For the nine months ended September 30, 2025, revenue decreased by $3.2 million, or 25%, to $9.659 million, primarily due to lower sales volume in the EMEA region[223] - Gross profit for the nine months ended September 30, 2025, decreased by $1.6 million to $5.174 million, while gross margin slightly increased to 54% from 53% in 2024[224][225] Expenses and Losses - Sales and marketing expenses for the nine months ended September 30, 2025, decreased by $0.7 million, or 13%, attributed to lower headcount and payroll expenses[227] - The company reported a net loss of $1.421 million for the three months ended September 30, 2025, an improvement of $0.651 million, or 31%, compared to a net loss of $2.072 million in 2024[211] - Research and development expenses decreased by $0.6 million, or 21%, for the nine months ended September 30, 2025, compared to the same period in 2024[228] - General and administrative expenses increased by $0.3 million, or 5%, for the nine months ended September 30, 2025, compared to the same period in 2024[229] Cash Flow and Working Capital - As of September 30, 2025, working capital was $5.9 million, down from $11.3 million as of December 31, 2024[236] - Net cash used in operating activities decreased by $0.9 million, or 11%, for the nine months ended September 30, 2025, compared to the same period in 2024[242] - Net cash provided by financing activities was $3.7 million for the nine months ended September 30, 2025, primarily from the B. Riley Promissory Note and common stock sales[244] - The company expects operating cash requirements to continue exceeding cash provided by operations in the near term[247] - Management estimates that the company's cash will fund operations into the first quarter of 2026[247] Strategic Initiatives - The company is exploring strategic transactions, which may include acquisitions in different industries, and expects that any such transaction would require stockholder approval and involve the issuance of a substantial amount of company securities[195] - The company is actively developing its channel partner program to enhance reimbursement claims for the Ekso Indego Personal device, with successful claims being processed through appeals[192] Other Financial Metrics - Interest expense, net decreased by 77% for the three months ended September 30, 2025, primarily due to lower interest related to promissory notes[218] - Unrealized gain on foreign exchange for the three months ended September 30, 2025, was de minimis compared to a gain of $0.634 million in 2024[220] - The gain on revaluation of warrant liabilities was negligible for the three months ended September 30, 2025, reflecting the volatility in stock price and other factors[219] - Interest expense decreased by 27% for the nine months ended September 30, 2025, compared to the same period in 2024[230] - Unrealized gain on foreign exchange was $2.0 million for the nine months ended September 30, 2025, compared to $0.2 million for the same period in 2024[233] - Total contractual obligations as of September 30, 2025, amounted to $6.188 million, with $4.682 million due within one year[249]

Financial Performance - Revenue for Q3 2025 was $4.2 million, a 2% increase year-over-year and a 105% sequential increase from Q2 2025[3] - Gross profit for Q3 2025 was $2.5 million, with a gross margin of approximately 60.3%, up from 53.5% in Q3 2024[4] - Net loss for Q3 2025 improved by 31% year-over-year to $1.4 million, or $0.54 per share, compared to a net loss of $2.1 million, or $1.53 per share, in Q3 2024[7] Expenses - Sales and marketing expenses decreased to $1.3 million in Q3 2025 from $1.8 million in Q3 2024, primarily due to lower payroll expenses[5] - Research and development expenses for Q3 2025 were $0.6 million, down from $0.8 million in Q3 2024[6] Strategic Initiatives - The company launched eksoUniversity and delivered its first official CEU certification to a physical therapist in Connecticut[9] - The company is exploring strategic transactions, which may include acquisitions or the sale of its current business[10] Cash and Assets - As of September 30, 2025, the company had cash of $2.7 million, down from $4.5 million at the end of 2024[8] - Total current assets decreased to $14.8 million as of September 30, 2025, from $18.8 million at the end of 2024[15] - Total liabilities as of September 30, 2025, were $12.0 million, down from $13.9 million at the end of 2024[15]

Core Viewpoint - Ekso Bionics Holdings, Inc. reported a revenue rebound and improved financial metrics for Q3 2025, indicating successful navigation through previous challenges and a focus on growth strategy while managing resources [3][10]. Financial Performance - For Q3 2025, the company recorded revenue of $4.2 million, a 2% increase year-over-year from $4.1 million in Q3 2024, and a 105% sequential increase from $2.1 million in Q2 2025 [3][10]. - Gross profit for Q3 2025 was $2.5 million, with a gross margin of approximately 60.3%, up from $2.2 million and 53.5% in Q3 2024, driven by higher margin Enterprise Health sales and lower device costs [4][10]. - Net loss for Q3 2025 was $1.4 million, or $0.54 per share, representing a 31% improvement from a net loss of $2.1 million, or $1.53 per share, in Q3 2024 [7][10]. Expense Management - Sales and marketing expenses decreased to $1.3 million in Q3 2025 from $1.8 million in Q3 2024, primarily due to lower payroll expenses related to the Employee Retention Credit [5]. - Research and development expenses were reduced to $0.6 million in Q3 2025 from $0.8 million in Q3 2024, also due to lower payroll expenses and headcount [6]. - General and administrative expenses decreased to $2.1 million in Q3 2025 from $2.3 million in Q3 2024, attributed to lower payroll expenses, partially offset by higher legal costs [7]. Strategic Initiatives - The company is exploring strategic transactions, which may include acquiring a business in a different industry or selling its current business, with no assurances that any transaction will occur [9][11]. - The company launched eksoUniversity and delivered its first official CEU certification to a physical therapist in Connecticut [10]. Cash Position - As of September 30, 2025, the company had cash of $2.7 million, down from $4.5 million at the end of 2024 [8][15]. Balance Sheet Overview - Total assets as of September 30, 2025, were $21.7 million, a decrease from $26.7 million at the end of 2024 [15]. - Total liabilities were $12.0 million, down from $13.9 million at the end of 2024, while stockholders' equity decreased to $9.7 million from $12.7 million [15].

Improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Investor Presentation October 2025 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Forw ...